Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients

Authors

  • Meiyu Fang Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Shengye Wang Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Yabing Zheng Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Xiangmin Kong Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Liyan Gong Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Youhao Qiu Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Yazhen Zhao Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou
  • Weimin Mao Zhejiang Thoracic Oncology Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou

DOI:

https://doi.org/10.3329/bjp.v7i3.11656

Keywords:

Docetaxel, Etoposide, Non-small cell lung cancer

Abstract

The present study evaluated the efficacy and safety of maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in patients with metastatic non-small cell lung cancer. The overall response rate in the docetaxel-cisplatin  phase was 30.4%, with complete response of 0, partial response of 28, stable disease of 39. Maintenance chemotherapy with oral etoposide was given in 67 patients. No complete response  was observed, but 10 patients presented with partial response  and 45 with stable disease . The median time to progression was 5.0 months; median overall survival time was 10 months and the 1-year survival rate was 41% during the maintenance therapy. Therapy with oral etoposide was well tolerated with the hematologic toxicities, fatigue and oral mucositis being the most frequent side effects. Docetaxel-cisplatin  chemotherapy followed by maintenance therapy with oral etoposide was well tolerated and moderately active against metastatic metastatic non-small cell lung cancer.

Downloads

Download data is not yet available.
Abstract
1519
Download
582 Read
228

References

Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002; 20: 3454-60.

Belani CP, Doyle LA, Aisner J. Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol. 1994; 34: S118-26.

Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006; 52: 155-63.

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899-909.

Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naive non-small-cell lung cancer in Taiwan. Lung Cancer 2007; 56: 363-69.

Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced nonsmall-cell lung cancer. J Clin Oncol. 2009; 27: 591-98.

Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol. 2003; 21: 3016-24.

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29: 2866-74.

Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005; 23: 3235-42.

Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R. Cellular and harmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005; 68: 110-18.

Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63: 1727-33.

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29: 3567-73.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.

Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. Cancer 1991; 67 Suppl: 231-44.

Loehrer PJ. Chronic oral etoposide: Trials at Indiana University and with the Hoosier Oncology Group. Semin Oncol. 1992; 19: 48-52.

Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 2008; 14: 4206-12.

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012; 13: 247-55.

Pedersen AG, Hansen HH. Etoposide (VP 16) in the treatment of lung cancer. Cancer Treat Rev. 1983; 10: 245-64.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomized phase III trial. Lancet. 2009; 373: 1525-31.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-50.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-51.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.

Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1992; 10: 292-96.

Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987; 316: 1435-40.

Downloads

Additional Files

Published

2012-09-24

How to Cite

Fang, M., S. Wang, Y. Zheng, X. Kong, L. Gong, Y. Qiu, Y. Zhao, and W. Mao. “Maintenance Therapy With Oral Etoposide Following First-Line Docetaxel-Cisplatin Chemotherapy in Metastatic Non-Small Cell Lung Cancer Patients”. Bangladesh Journal of Pharmacology, vol. 7, no. 3, Sept. 2012, pp. 192-8, doi:10.3329/bjp.v7i3.11656.

Issue

Vol. 7 No. 3 (2012)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).